Journal of Oncology

Bioinformatics in Cancer and Immune Microenvironment


Publishing date
01 Jul 2022
Status
Published
Submission deadline
04 Mar 2022

Lead Editor
Guest Editors

1Neonatal Department, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China

2Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China

3Department Pain Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China

4University of Verona Medical School, Verona, China


Bioinformatics in Cancer and Immune Microenvironment

Description

Tumor cells do not exist in isolation in the microenvironment of malignancy but rather in a diverse ecosystem that includes not only heterogeneous tumor cell clones, but also normal cell types like fibroblasts, vasculature, and a large pool of immune cells at various stages of activation and differentiation. As a consequence, there is now a complicated interaction of different cellular signaling pathways with the immune cell component influencing cancer development and therapeutic response. To capitalize on potential therapeutic and biomarker findings, it is challenging and time-consuming to thoroughly and systematically characterize these different cell types from diverse tumor samples using immunohistochemistry. We have now entered an era of digital cancer treatment, fueled by the increasing availability of omics technologies, in which varied and global molecular profiling may drive therapeutic discovery and predict immunotherapy responses. Computationally extracting cell-type specific information directly from bulk tumors is one promising answer to this problem. The benefit of using bioinformatics to predict accurate immune signatures from bulk native tumor tissue is that the functional intracellular and intercellular transcriptome profiles are preserved, whereas when purified immune cells are isolated from native tissue, the molecular profiles will have inherently different patterns. Such in silico methods are beneficial because they may capture cell-type specific characteristics as well as cell-cell interactions at the tissue system level.

Predicting tumor patterns accurately and completely is a significant problem to solve, especially considering the effectiveness of immunotherapeutic medication therapy for many human malignancies. This is particularly difficult for subgroups of closely similar immune cell phenotypes with modest gene expression variations but significant functional differences. It will be very beneficial to use bioinformatics strategies to profile the tumor immune landscape because it will allow us to systematically profile one immune cell population's patterns and immune cell networks in tumors with higher resolution, which will aid in the discovery of immune-modulatory drugs.

The goal of this Special Issue is to bring together original research and review articles that will help researchers better understand the complex interactions that exist between tumors, immune cells, and the microenvironment, as well as the discovery of new biomarkers and molecular targets in various cancers.

Potential topics include but are not limited to the following:

  • Bioinformatics research into new cancer diagnosis and treatment methods based on the immune microenvironment
  • Immunological, gene regulatory, and pathophysiological mechanisms involved in carcinogenesis
  • The crosstalk between immune and nonimmune cells in the tumor microenvironment
  • Drug target discovery and targeted drug design
  • Therapeutic strategies that modulate the immune response
  • Meta-analysis to identify the function of tumor microenvironment in cancer

Articles

  • Special Issue
  • - Volume 2022
  • - Article ID 9411692
  • - Research Article

Essential m6A Methylation Regulator HNRNPC Serves as a Targetable Biomarker for Papillary Renal Cell Carcinoma

Jiajin Wu | Yuang Wei | ... | Zengjun Wang
  • Special Issue
  • - Volume 2022
  • - Article ID 1802706
  • - Research Article

Identification of Potential Biomarkers for Progression and Prognosis of Bladder Cancer by Comprehensive Bioinformatics Analysis

Zhiyong Tan | Shi Fu | ... | Jiansong Wang
  • Special Issue
  • - Volume 2022
  • - Article ID 6988923
  • - Research Article

Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma

Guoqiang Sun | Ganggang Miao | ... | Weiwei Tang
  • Special Issue
  • - Volume 2022
  • - Article ID 5224434
  • - Research Article

Development an Immune-Related MicroRNA Risk Index in Hepatocellular Carcinoma

Shun Zhou | Jian Xu | ... | Lijuan Meng
  • Special Issue
  • - Volume 2022
  • - Article ID 3623591
  • - Research Article

Protective Prognostic Biomarkers Negatively Correlated with Macrophage M2 Infiltration in Low-Grade Glioma

Yunyang Zhu | Zhaoming Song | ... | Gang Chen
  • Special Issue
  • - Volume 2022
  • - Article ID 3997562
  • - Research Article

Identification of a Ferroptosis-Related Prognostic Gene PTGS2 Based on Risk Modeling and Immune Microenvironment of Early-Stage Cervical Cancer

Chang Zou | Fangfang Xu | ... | Shaohua Xu
  • Special Issue
  • - Volume 2022
  • - Article ID 5426887
  • - Research Article

Hyper-Methylated Hub Genes of T-Cell Receptor Signaling Predict a Poor Clinical Outcome in Lung Adenocarcinoma

Zixin Hu | Chongxiang Xue | ... | Huijuan Cui
  • Special Issue
  • - Volume 2022
  • - Article ID 8281067
  • - Research Article

A Novel Four Genes of Prognostic Signature for Uveal Melanoma

Yan Liu | Huibin Du | ... | Xiaohui Lv
  • Special Issue
  • - Volume 2022
  • - Article ID 8901326
  • - Review Article

Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy

Nasrin Aktar | Chen Yueting | ... | Xiaohui Zhou
  • Special Issue
  • - Volume 2022
  • - Article ID 1531474
  • - Research Article

Immune Infiltrates of m5C RNA Methylation-Related LncRNAs in Uterine Corpus Endometrial Carcinoma

Wen-Xiu Gu | Yan Chen | Wei Wang
Journal of Oncology
 Journal metrics
See full report
Acceptance rate6%
Submission to final decision136 days
Acceptance to publication68 days
CiteScore3.900
Journal Citation Indicator-
Impact Factor-
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.